Results of Phase 3 Clinical Trial of New Tuberculosis Drug Regimen Published in New England Journal of Medicine
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds
TB Alliance, a not-for-profit with the mission of discovering and developing better, faster and affordable treatments, announced the appointment of
TB Alliance, a not-for-profit organization with the mission of developing better, faster and affordable treatments for tuberculosis (TB), announced the
Researchers at the University of Sheffield, Imperial College London, and TB Alliance have found evidence that a large gap exists
Shorter TB treatment regimens will reduce the out-of-pocket expenses incurred by both patients and their family members, who often act
For the first time, the upcoming International AIDS Conference will feature a dedicated hub for discussing the deadly duo of
TB Alliance, a not-for-profit organization dedicated to developing better, faster, and affordable treatments for tuberculosis (TB), announced the appointment of
Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both
TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that